Vis enkel innførsel

dc.contributor.authorHaugeberg, Glenn
dc.contributor.authorHelgetveit, Knut
dc.contributor.authorFørre, Øystein Thorleiv
dc.contributor.authorGaren, Torhild Oddveig
dc.contributor.authorSommerseth, Hege
dc.contributor.authorPrøven, Anne
dc.date.accessioned2015-09-21T13:17:45Z
dc.date.accessioned2016-04-21T11:03:53Z
dc.date.available2015-09-21T13:17:45Z
dc.date.available2016-04-21T11:03:53Z
dc.date.issued2014
dc.identifier.citationBMC Musculoskeletal Disorders 2014, 15(1)nb_NO
dc.identifier.issn1471-2474
dc.identifier.urihttp://hdl.handle.net/11250/2386745
dc.description.abstractBackground: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). Biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to be superior to synthetic DMARDs to reduce bone destruction including generalized bone loss in RA. Our aim was to study short- and long term changes in hip and spine bone mineral density (BMD) in early RA patients treated during the first decade with available biologic DMARDs. Methods: RA patients diagnosed at an out-patient clinic between 1999 and 2001 were consecutively enrolled. Demographic, disease and treatment data were collected and BMD was assessed by dual energy X-ray absorptiometry at baseline and after 2, 5 and 10 years. Results: The 92 included RA patients had a baseline mean age (SD) of 50.9 (13.3) years and symptom duration of 12.4 (6.7) months, 62.0% were women and 66.3% were RF positive. In the first 2 years ever use of biologic DMARDs was 18.5%, synthetic DMARDs 91.3% and prednisolone 62.0% whereas the figures for the subsequent 8 years were 62.6%, 89.2% and 51.4%, respectively. The annual rate of BMD loss in the first 2 years and the subsequent 8 years was at femoral neck −1.00% vs. −0.56%, at total hip −0.96% vs. −0.41% and at spine L1−4 -0.42% vs. 0.00%. Conclusions: Our study adds evidence that aggressive anti-inflammatory treatment including biologic DMARDs reduces the rate of bone loss in RA. Indicating that the burden of osteoporosis is reduced in RA patients treated in clinical practice in the new millennium.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.rightsNavngivelse 3.0 Norge*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/no/*
dc.titleGeneralized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment eranb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.date.updated2015-09-21T13:17:45Z
dc.source.volume15nb_NO
dc.source.journalBMC Musculoskeletal Disordersnb_NO
dc.identifier.doi10.1186/1471-2474-15-289
dc.identifier.cristin1200632
dc.description.localcode© Haugeberg et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 3.0 Norge
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 3.0 Norge